Grassi Investment Management lessened its position in shares of Eli Lilly And Co (NYSE:LLY) by 1.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 86,948 shares of the company’s stock after selling 1,393 shares during the period. Eli Lilly And Co accounts for 1.4% of Grassi Investment Management’s holdings, making the stock its 19th biggest holding. Grassi Investment Management’s holdings in Eli Lilly And Co were worth $9,330,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Eli Lilly And Co during the second quarter worth $114,000. Legacy Advisors LLC raised its stake in Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after buying an additional 733 shares during the last quarter. Fort L.P. acquired a new stake in Eli Lilly And Co in the second quarter worth $121,000. Financial Management Professionals Inc. acquired a new stake in Eli Lilly And Co in the second quarter worth $128,000. Finally, Twin Tree Management LP grew its holdings in Eli Lilly And Co by 97.9% in the second quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock worth $136,000 after purchasing an additional 786 shares during the period. 76.56% of the stock is owned by institutional investors and hedge funds.
LLY has been the subject of a number of research reports. Credit Suisse Group raised their price target on shares of Eli Lilly And Co from $82.00 to $84.00 and gave the stock an “underperform” rating in a report on Thursday, June 21st. DZ Bank restated a “hold” rating on shares of Eli Lilly And Co in a report on Friday, June 22nd. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a report on Friday, June 29th. Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Monday, July 9th. Finally, Jefferies Financial Group set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Sunday, July 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $107.88.
In other Eli Lilly And Co news, Director Jackson P. Tai acquired 2,168 shares of Eli Lilly And Co stock in a transaction dated Thursday, July 26th. The stock was purchased at an average cost of $95.22 per share, for a total transaction of $206,436.96. Following the completion of the acquisition, the director now directly owns 53,228 shares of the company’s stock, valued at $5,068,370.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $98.74, for a total transaction of $20,241,700.00. Following the transaction, the insider now owns 121,121,794 shares of the company’s stock, valued at $11,959,565,939.56. The disclosure for this sale can be found here. Insiders have sold 1,785,575 shares of company stock valued at $180,166,130 over the last quarter. Corporate insiders own 0.11% of the company’s stock.
Shares of NYSE LLY opened at $110.48 on Friday. The stock has a market cap of $115.25 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.20. The firm had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the company earned $1.11 earnings per share. As a group, research analysts anticipate that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.